Janssen’s Tremfya gets FDA approval for active psoriatic arthritis

Janssen’s Tremfya gets FDA approval for active psoriatic arthritis

Source: 
Pharmaceutical Business Review
snippet: 

Janssen Pharmaceutical has secured approval from the US Food and Drug Administration (FDA) for Tremfya (guselkumab) for the treatment of active psoriatic arthritis (PsA) in adults.